Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
Davids MS, Ryan CE, Lampson BL, Ren Y, Tyekucheva S, Fernandes SM, Crombie JL, Kim AI, Weinstock M, Montegaard J, Walker HA, Greenman C, Patterson V, Jacobson CA, LaCasce AS, Armand P, Fisher DC, Lo S, Olszewski AJ, Arnason JE, Ahn IE, Brown JR. Davids MS, et al. Among authors: tyekucheva s. J Clin Oncol. 2024 Dec 7:JCO2402503. doi: 10.1200/JCO-24-02503. Online ahead of print. J Clin Oncol. 2024. PMID: 39645236
Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
Davids MS, Lampson BL, Tyekucheva S, Wang Z, Lowney JC, Pazienza S, Montegaard J, Patterson V, Weinstock M, Crombie JL, Ng SY, Kim AI, Jacobson CA, LaCasce AS, Armand P, Arnason JE, Fisher DC, Brown JR. Davids MS, et al. Among authors: tyekucheva s. Lancet Oncol. 2021 Oct;22(10):1391-1402. doi: 10.1016/S1470-2045(21)00455-1. Epub 2021 Sep 14. Lancet Oncol. 2021. PMID: 34534514 Clinical Trial.
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR; Blood Cancer Research Partnership of the Leukemia & Lymphoma Society. Davids MS, et al. Among authors: tyekucheva s. Lancet Haematol. 2019 Aug;6(8):e419-e428. doi: 10.1016/S2352-3026(19)30104-8. Epub 2019 Jun 14. Lancet Haematol. 2019. PMID: 31208944 Free PMC article. Clinical Trial.
Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome.
Davids MS, Rogers KA, Tyekucheva S, Wang Z, Pazienza S, Renner SK, Montegaard J, Ihuoma U, Lehmberg TZ, Parry EM, Wu CJ, Jacobson CA, Fisher DC, Thompson PA, Brown JR. Davids MS, et al. Among authors: tyekucheva s. Blood. 2022 Feb 3;139(5):686-689. doi: 10.1182/blood.2021011386. Blood. 2022. PMID: 34788401 Free PMC article. Clinical Trial.
Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia.
Lampson BL, Gupta A, Tyekucheva S, Mashima K, Petráčková A, Wang Z, Wojciechowska N, Shaughnessy CJ, Baker PO, Fernandes SM, Shupe S, Machado JH, Fardoun R, Kim AS, Brown JR. Lampson BL, et al. Among authors: tyekucheva s. J Clin Oncol. 2023 Feb 10;41(5):1116-1128. doi: 10.1200/JCO.22.00269. Epub 2022 Oct 31. J Clin Oncol. 2023. PMID: 36315919 Free PMC article.
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
Ryan CE, Brander DM, Barr PM, Tyekucheva S, Hackett LR, Collins MC, Fernandes SM, Ren Y, Zhou Y, McDonough MM, Walker HA, McEwan MR, Abramson JS, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR, Davids MS. Ryan CE, et al. Among authors: tyekucheva s. Leukemia. 2023 Apr;37(4):835-842. doi: 10.1038/s41375-023-01830-2. Epub 2023 Jan 30. Leukemia. 2023. PMID: 36717653 Clinical Trial.
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia.
Gadi D, Griffith A, Tyekucheva S, Wang Z, Rai V, Vartanov A, Thrash E, Fernandes SM, Lehmberg TZ, Lee B, Martindale SP, Machado JH, Odejide O, Armand P, Fisher DC, Arnason J, Davids MS, Lederer JA, Brown JR. Gadi D, et al. Among authors: tyekucheva s. Leukemia. 2022 Mar;36(3):723-732. doi: 10.1038/s41375-021-01441-9. Epub 2021 Nov 6. Leukemia. 2022. PMID: 34743191 Free PMC article. Clinical Trial.
Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale S, Zhou Y, Ren Y, Tyekucheva S, Kim AS, Fernandes SM, Saksena G, Rhrissorrakrai K, Levovitz C, Danysh BP, Slowik K, Jacobs RA, Davids MS, Lederer JA, Zain R, Smith CIE, Leshchiner I, Parida L, Getz G, Brown JR. Naeem A, et al. Among authors: tyekucheva s. Blood Adv. 2023 May 9;7(9):1929-1943. doi: 10.1182/bloodadvances.2022008447. Blood Adv. 2023. PMID: 36287227 Free PMC article.
67 results